中国生物制药(01177)公布,该集团自主研发的创新药TQB3122“PARP1抑...中国生物制药(01177)公布,该集团自主研发的创新药TQB3122“PARP1抑制剂”的新药临床试验申请(IND)已获得中国国家药品监督管理局 (NMPA)受理,拟用于治疗晚期恶性肿瘤。TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂,通过双重机制发挥抗肿瘤作用:一方面,竞争性抑制...
Source Link中国生物制药(01177)公布,该集团自主研发的创新药TQB3122“PARP1抑...中国生物制药(01177)公布,该集团自主研发的创新药TQB3122“PARP1抑制剂”的新药临床试验申请(IND)已获得中国国家药品监督管理局 (NMPA)受理,拟用于治疗晚期恶性肿瘤。TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂,通过双重机制发挥抗肿瘤作用:一方面,竞争性抑制...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.